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Abstract
By combining tissue engineering techniques with human-induced pluripotent stem cell 
(hiPSC) technology, human-derived engineered cardiac tissues (ECTs) have been devel-
oped using several cell lineage compositions and 3-dimensional geometries. Although 
hiPSC ECTs are relatively immature compared with native adult heart tissues, they have 
promising potential as a platform technology for drug-screening and disease model-
ing, and as grafts for hiPSC-based regenerative heart therapy. This chapter provides the 
focused overview of the current status of cardiac tissue engineering technology and its 
possible application.
Keywords: iPS cell, engineered cardiac tissue, tissue engineering, drug screening, 
disease modeling, cardiac regeneration
1. Introduction
With the progress of tissue engineering technology in the last decade, many kinds of engi-
neered cardiac tissues (ECTs) have been developed and reported. These tissues possess stri-
ated myofibers which recapitulate unique contractile function of heart tissues. Takahashi, 
Yamanaka, and colleagues developed iPSCs from mice in 2006 and from human next year 
[1, 2]. Human iPS cells (hiPSCs) have the potential to differentiate into cardiomyocytes and 
other cardiac lineage cells. Recently, the efficiency of cardiac differentiation has rapidly 
improved, which makes it possible to robustly induce cardiac lineage cells [3–6]. By using 
cardiac cells derived from hiPSCs as a cell source for ECT generation, the potential of ECTs 
has expanded. The present chapter overviews the current status of ECT technology and its 
possible application.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Methods for generating engineered cardiac tissues
2.1. Cell sheet technology
Okano, Shimizu and colleagues have developed a culture surface grafted with temperature-
responsive polymer, poly(N-isopropyl acrylamide) (PIPAAm) [7]. This system enables con-
fluent cells to detach themselves from the surface while maintaining a sheet structure simply 
by reducing the culture temperature. The cell sheets are fabricated without the use of exog-
enous matrices. It has endogenous matrix layer at the bottom side, and it secures biological 
attachment to the recipient heart surface within 30 min [8]. This scaffold-free tissue is a thin 
sheet, and three-dimensional thicker structure can be obtained by stacking several sheets. 
However, stacking more than three layers (approximately 80 μm thickness) triggers cell death 
at the center due to hypoxia [9]. At our lab, we overcame this limit by stacking cell sheets with 
gelatin hydrogel microspheres (GHM) [10]. Five-layered cell sheets with GHM displayed bet-
ter cell viability in vitro compared with the control cell sheet without GHM. Furthermore, cell 
sheet modification with GHM improved the retention of grafted cell sheets on the rat heart 
epicardial surface after myocardial infarction. We succeeded in generating over 1 mm thick 
constructs from 15 sheets using this technology.
2.2. Biomaterials
Cardiomyocytes and other cells are embedded in biomaterials, such as collagen I, matrigel, 
and/or fibrin in a casting mold. Exogenous gel matrix promotes self-assembly of cells lead-
ing to form a tissue structure. The first successful cardiac tissue fabrication by this method 
was reported in the year 1997 [11]. Fixed anchors in these molds generate static strain, which 
enhances the cell alignment and contractile function. The geometry of mold controls the final tis-
sue architecture, and a variety of tissue shapes have been formulated, including linear [12–16], 
circular [17], and mesh structures (Figure 1) [18–20]. By applying engineering manufacturing 
methods, it may be possible to automate the process of generating small-sized ECTs, leading 
to the development of high throughput in vitro analysis systems [21, 22]. In fact, recently, 3D 
bio-printing technology has been applied and provided the possibility of creating more com-
plicated structures reproducibly by printing both scaffold matrix and living cells [23].
2.3. Prefabricated matrix
Biomaterials provide a ‘soft’ environment for the cells to grow in. On the other hand, syn-
thetic microporous (‘spongy’) scaffolds made from alginate, collagen, and gelatin or other 
stiffer materials, such as polystyrene, PLLA (Poly-L-Lactide Acid), PLGA (Poly(lactic-co-
glycolic acid)) and PCL (Polycaprolactone), have also been tested [24, 25]. The advantage of 
this method is that these rigid scaffolds contribute to engineering any desired structure and 
size with mechanical stability. However, the maturation of various mesodermal cells is matrix 
stiffness dependent, and therefore both the biomaterial gel and the supporting mold may 
impact cell maturation and survival [26].
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2.4. Decellularized tissue
Deccllurization of a whole heart is achieved by the treatment with sodium dodecyl sulfate 
(SDS) and Triton X-100 under Langendorf perfusion [27]. The decellularized tissue maintains 
most of the tissue contents and function of the extracellular matrix. Hence, decellularized tissue 
provides a native scaffold which can support repopulation by mesoderm lineage cells. These 
decellularized tissues may be advantageous in the generation of in vitro cardiac tissues [28, 29].
3. Maturation of the tissue
3.1. Cellular contents
A heart tissue is composed of multiple cell types including cardiomyocytes, fibroblasts, endo-
thelial cells, and smooth muscle cells. In human hearts, cardiomyocytes account for 25-50% of 
total cells, occupying around 70% of the whole volume [30]. Many reports have demonstrated 
that non-myocytes support the maturation of cardiomyocytes and play a significant role in 
both myocardial structure and function [13, 16, 19].
We induced cardiomyocytes (CM), endothelial cells (EC), and vascular mural cells (MC) from 
hiPSCs, and generated ECTs from several formulations of cardiomyocytes and non-myocytes, 
Figure 1. Generation of a mesh ECT by biomaterial-based technique. (a) Schematic diagram for a mesh ECT generation. 
Cardiomyocytes (CM), endothelial cells (EC), and mural cells (MC) are induced from human iPS cells (h-iPSCs) using 
two different protocols. Cells and collagen-based matrix were combined and poured into custom polydimethylsiloxane 
(PDMS) molds at day 0 and cultured for 14 days. (b) Representative image of a PDMS mold (left) and a mesh ECT (right). 
Scale bar: 10 mm. (Reproduced from Ref. [20] with permission).
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such as CM+EC, CM+MC, and CM+EC+MC [16]. According to in vitro force measurement, 
CM+EC+MC ECTs showed most advanced electrophysiological properties. Furthermore, his-
tological analysis revealed CM+EC+MC possessed more unidirectionally aligned myofiber 
with mature sarcomeric structures (Figure 2).
The mechanism for the improvement of tissue maturation as the result of a more complex lin-
eage mixture is still unknown. Evidence is emerging that cardiomyocytes and fibroblasts are 
electrically coupled, which may modulate electrophysiologic function [31]. Direct interaction 
of different cell types or paracrine effects can be considered. It is reported that extracellular 
matrix derived from cardiac fibroblast supported the proliferation in vitro and indicated the 
usefulness of the coculture [32].
3.2. Effects of extended culture duration on CM and ECT maturation and function
Cardiomyocytes derived from pluripotent stem cells mature early in culture but are arrested 
at the late embryonic stage under 2-dimensional (2D) culture condition [33]. Meanwhile, it is 
widely recognized that cardiomyocytes in a 3-dimensional (3D) cardiac tissue acquire a more 
mature phenotype than those in 2D culture [25, 34].
In our study, we prolonged culture duration of mesh ECTs from 14 to 28days [20]. Long-
cultured constructs showed the tendency to augment the active contractile force along with 
the increase of beating frequency from 1.5Hz to 2.5Hz and maintained greater force compared 
to 14-day constructs. The shift from a negative to a neutral force-frequency relationship in 
28-day constructs represents sustained functional maturation as well as more rapid force gen-
eration and relaxation cycle, and the ability to capture higher pacing frequency. Additional 
culture duration enhanced myofiber alignment along with the expression of several genes 
related to ion channels and gap junction (Figure 3).
3.3. Impact of culture condition on ECT maturation and function
In order to expand the dimension of ECTs, it is necessary to improve the distribution of oxy-
gen and nutrient throughout tissues. Direct perfusion of culture medium reduces the gradi-
ents associated with diffusional mass transport between the construct surfaces and the inner 
phase and improves the microenvironmental conditions within ECTs. [35–37]. In addition to 
the increase of cellularity at the center of ECTs, perfusion system contributes to the matura-
tion of cardiomyocytes and the tissue structure. It is reported that even the simple rocking 
dynamic culture yields engineered myocardium with near-adult functional output [38]. The 
system accelerates force generation and conduction velocity probably due to the activation of 
mTOR signaling.
For generating ECTs, especially from biomaterial-based technique, materials from other 
sources, such as collagen derived from rat or matrigel, have been widely used with xeno-
serum containing culture medium. Tiburcy and colleagues modified their methods toward 
clinical application and developed a formulation for generating ECTs by using medical grade 
bovine collagen and maintaining them under serum-free defined condition [19]. This modifi-
cation provided a proof-of-concept for a universally applicable technology for the engineering 
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Figure 2. Electromechanical properties and structural maturation of hiPSC-ECTs. (a) Schematic diagrams for generationg 
3 types of ECTs containing cardiomyocytes (CM), endothelial cells (EC), and/or mural cells (MC) (upper) and the 
proportions of each cell type (lower) [n = 8 (CM+ EC), 7 (CM+ MC), and 12 (CM+ EC+ MC). (b–d) Results of contractile 
force measurements [n = 8 (CM+ EC), 7 (CM+ MC), and 12 (CM+ EC+ MC)]. (b) Maximum capture rate (left), relaxation 
time (center) and excitation threshold voltage (right) (c) Relationship between active force and pacing frequency 
(2Hz to 3.5Hz). (d) Young’s modulus of ECTs. NS, not significant; *P < 0.05,**P < 0.01, ***P < 0.001. (e) Representative 
alignment analysis using cTnT-stained images after 2-dimensional (2D) and 3-dimensional (3D) culture for 3 types of 
ECTs (left). Calculated concentration parameter (κ ) (right) [n =3 (2D) and 5 (each 3D)]. Larger values of κ represent 
greater alignment to a single direction. cTnT, cardiac troponin T; Deg, degree. (f) Representative transmission electron 
microscopic images for each type of ECT cultured for 4 weeks. Arrows indicate myofibers. N, nucleus; Mt, mitochondria; 
I, I-band; A, A-band; Z, Z-line. (Reproduced from Ref. [16] with permission).
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cardiac tissue. In addition, ECTs generated by this condition displayed advanced cardiomyo-
cyte maturation compared to the conventional methods [19].
3.4. Role of mechanical loading on ECT maturation and function.
Several in vitro ECT studies revealed the impact of uniaxial mechanical loading on the align-
ment of cardiomyocytes and functional maturation. The simplest system for that is the two 
fixed anchors which generate static strain on the tissue between them. Furthermore, cyclic 
stress conditioning markedly increases cardiomyocyte hypertrophy and proliferation rates ver-
sus unconditioned constructs [13]. We demonstrated that ECTs displayed a broad spectrum of 
altered gene expression in response to cyclic stretch, reflecting a complex regulation of prolifer-
ation, differentiation, and architectural alignment of cardiomyocytes and non-cardiomyocytes 
within ECTs [39].
Electrical stimulation is considered to be another important cue for further maturation 
of tissues [40]. Nunes and colleagues subjected their engineered tissues, named biowires, 
Figure 3. Effects of extended culture duration on mesh ECT maturation. (a) Averaged normalized active force-time 
curves for mesh ECT cultured for either 14 (blue, D14) or 28 (red, D28) (n = 6) days under 2 Hz electrical stimulation. 
Contraction time (CT) or relaxation time (RT) represents the time of 90% increase or decrease of force respectively. 
Comparison of (b) contraction time 90% (n = 6; ***P < 0.01), (c) relaxation time 90% (***P < 0.001) at 2 Hz pacing, (d) 
maximum capture rate (n = 6; ***P < 0.001), (e) force-frequency relationship (n = 6; *P < 0.05 to ***P < 0.001 vs. D14), and 
(f) cardiomyocyte alignment concentration (κ), [n = 4 (D14) and n = 3 (D28); ***P < 0.001]. (g), (h) Q-PCR analysis (n = 3; 
*P < 0.05 to ***P < 0.001). cTnT level was lower in D28, and other genes were normalized to the value of cTnT expression. 
(Reproduced from Ref. [20] with permission).
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on electrical stimulation at up to 6 Hz [41]. Biowires subjected to electrical stimulation 
had markedly increased myofibril ultrastructural organization, elevated conduction 
velocity and improved both electrophysiological and Ca2+ handling properties compared 
to non-stimulated controls. These changes were in agreement with cardiomyocyte matu-
ration and were dependent on the stimulation frequency.
Another group created a system which applied combined electromechanical stimulation 
mimicking isovolumic contraction and confirmed the improvement of functional properties 
over electrical or mechanical stimulation alone. In the report, the timing of the combined 
stimulation greatly affected the electrophysiological properties of ECTs [42].
4. Applications of ECTs
4.1. Drug screening
Cardiotoxicity is one of the main causes of drug withdrawal from the market [43, 44]. To 
evaluate the safety and effectiveness of drugs, several kinds of pre-clinical studies are per-
formed using non-human models. However, these models occasionally show incorrect 
results, such as pseudo-negative, due to the difference of electrophysiology in other species 
[45]. By using hiPSC technology, effects to humans can be examined from the early stage 
[46]. Moreover, hiPSC-derived ECTs are expected to be more specific and sensitive platforms 
for drug screening [14].
We have developed a 3D cardiac tissue model which reproduces Torsade de Pointes (TdP) 
showing both a typical polymorphic extracellular field potential and meandering spiral wave 
re-entry upon treatment with IKr channel blockers [47]. It is generated from hiPSC-derived 
cardiomyocytes and mesenchymal cells using the cell sheet technology. The appearance of 
TdP-like waveforms was significantly higher in this 3D model compared with 2D monolayer 
conditions indicating that the multilayered 3D structure is an essential factor for this arrhyth-
mia along with the coexistence of non-cardiomyocytes.
Many groups have developed various high throughput screening formats, such as strip 
format [48] and heart-on-chip [21, 49], and confirmed the similarity of hiPSC-derived engi-
neered tissues with native heart tissues [14, 50–52]. Video optical recording system set 
up in a usual CO
2
 incubator is also useful to continuously monitor contractile abilities of 
tissues [48].
Cardiomyocytes from hiPSCs are at the premature stage, and even ECTs generated to date 
remain immature compared to native adult myocardium. Hence, further cues for maturation 
as described above is necessary to imitate native tissues more precisely [51].
4.2. Disease modeling
iPS cells derived from a patient with a known genetic mutation for the disease can provide 
the disease model, which may offer a useful strategy for understanding the mechanism of the 
disease and exploring a new treatment modality.
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Cardio-facio-cutaneous syndrome (CFCS) is one of the RASopathies, and cardiac abnormali-
ties are the most common findings among CFCS, including hypertrophic cardiomyopathy 
(HCM) in approximately 40% of patients. Nearly 75% of patients with CFCS exhibit muta-
tions in BRAF, which encodes a serine/threonine kinase and a direct effector of Ras. Cashman 
and colleagues created 3D human engineered cardiac tissue model of HCM using human 
cardiomyocytes yielded by directed differentiation of iPSCs established from a patient with 
CFCS carrying an activated BRAF mutation [53].
Chronic catecholamine overstimulation contributes to heart failure progression. Overs-
timulation of ECTs with norepinephrine provides a simulation of a human heart failure 
Figure 4. Therapeutic effects of hiPSC-mesh ECT implantation in a rat myocardial infarction model. (a) Schematic 
timeline of surgery. A mesh ECT matured in vitro for 14 days (or sham suture) is implanted in a nude rat (week 0) 1 week 
after the induction of myocardial infarction by ligating left anterior descending artery (LAD). Echocardiogram (Echo) 
is performed prior to LAD ligation at week-1 (W-1), prior to implantation at week 0 (W0), then week 2 (W2) and week 4 
(W4). (b) Grafted mesh ECT on the heart surface covering infarction site. (c) Representative Masson’s trichrome staining 
images of sham treated (left) and mesh ECT implanted (right) rat hearts at W4. Scale bar: 2 mm. Red dotted line indicates 
engrafted area. (d) Comparison of scar area (% of LV area) at W4 (n=5, *P<0.05 Implant versus Sham). (e-g) Results of 
echocardiogram [n=5 (Implant, red solid line) and 5 (Sham, blue dotted line)]. (e) Left ventricular end diastolic area 
(LVAd; mm2), (f) ejection fraction, EF (%), and (g) cardiac index, CI (mL/min/kg) (*P<0.05 Implant versus Sham at W4). 
(Reproduced from Ref. [20] with permission).
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phenotype [19]. Tissues responded to chronic catecholamine toxicity with contractile dys-
function, cardiomyocyte hypertrophy, cardiomyocyte death, and NT-proBNP release, which 
are classical hallmarks of heart failure. Notably, the pathological phenotype could be par-
tially or fully prevented by β1- or α1-adrenoreceptor blockade, demonstrating the applicabil-
ity of ECTs in the in vitro simulation of heart failure and its prevention by pharmacological 
means.
4.3. Transplantation therapy
HiPSCs are now one of the most promising cell sources for cardiac regenerative cell therapy 
[54–56]. There are major methods of cell delivery, including intracoronary or intramuscular 
injection of dispersed cells and epicardial transplantation of engineered tissues [57]. It is pos-
sible to deliver a large number of differentiated cells with organized architecture by ECT 
implantation. The grafted tissues survive and support the heart wall, which overcomes the 
problem of poor retention rate following cell injection [34].
A variety of studies has revealed the efficacy of ECT implantation for myocardial struc-
tural and functional recovery in injured hearts of several animal models [6, 10, 58, 59]. 
We implanted ECTs in an athymic nude rat myocardial infarction model. ECTs with 
vascular cells displayed the invasion of vasculature from the host heart to the tissue 
and their perfusion. Survived ECTs replaced the ventricular wall in the injured area and 
prevented the scar formation after myocardial infarction and improved cardiac function 
(Figure 4). ECTs survived during 4-week follow-up period [16, 20]. However, further 
work is required to identify the underlying mechanism for the functional recovery. 
Meanwhile, the first transplantation of cardiac progenitor patch derived from human 
embryonic stem cells in a severe heart failure patient was performed in France, offering 
an encouraging result [60].
5. Conclusion
In this chapter, we have reviewed several aspects of current cardiac tissue engineering tech-
nologies and presented the possible applications of these tissues for in vitro drug toxicity 
testing, human disease modeling, and paradigms for myocardial recovery with muscle 
replacement following injury. This rapidly evolving new field is now incorporating manu-
facturing process to expand the scalability and reduce the cost of generating these novel engi-
neered in vitro myocardial tissues.
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